世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

乳がん生体組織検査(リキッドバイオプシー)市場:血中循環腫瘍毎、地域毎、エンドユーザ、投資、市場動向、プラットフォーム比較、競争市場 - 2023年までの世界市場予測

Breast Cancer Liquid Biopsy Market by Circulating Biomarkers, Region, End User, Investments, Market Dynamics, Platform Comparison (NGS, PCR), Competitive Landscape (Acquisition, Mergers, Collaboration, Competitive technology) - Global Forecasts to 2022

 

出版社 出版年月電子版価格 ページ数図表数
MarketsandMarkets
マーケッツアンドマーケッツ
2018年8月US$5,650
シングルユーザライセンス
83 26

サマリー

幅広い市場に関する調査レポートを出版しているマーケッツアンドマーケッツ(MarketsandMarkets)の乳がん生体組織検査(リキッドバイオプシー)市場に関する調査レポートです。

“Global breast cancer liquid biopsy market projected to grow at a CAGR of 23.1%”

The global breast cancer liquid biopsy market is estimated to grow at a CAGR of 23.1% from 2017 to 2022, from USD 145.4 million in 2017 to reach USD 411.1 million by 2022. Increasing prevalence of breast cancer, increasing preference for noninvasive procedures, and availability of funding for liquid biopsy R&D are some of the key factors driving the growth of the market. Unclear regulatory and reimbursement scenario is one of the major challenges faced by the market.

“Cell-free DNA to register the highest CAGR during the forecast period”

Based on circulating biomarkers, the market is categorized into circulating tumor cells (CTCs), cell-free DNA (cfDNA), extracellular vesicles (EVs), and other circulating biomarkers. The cfDNA segment is the fastest-growing segment in the circulating biomarkers market during the forecast period. This is due to the growing interest in cfDNA research from biofluids such as the blood of cancer patients as a means of disease diagnosis and therapeutic monitoring.

“Reference laboratories to register the largest share during the forecast period”

Based on end user, the market is categorized into reference laboratories, hospitals and physician laboratories, and other end users. The reference laboratories segment is the largest end-user segment of the global breast cancer liquid biopsy market. Reference laboratories are well-equipped large laboratories with facilities for genomic testing of samples, thus receiving major share of samples from hospitals and private practitioners.

“Asia Pacific to witness the highest growth during the forecast period (2017-2022)”

North America is expected to account for the largest share of the global breast cancer liquid biopsy market in 2017, while Asia Pacific is expected to witness the highest growth during 2017 to 2022. Growing demand for non-invasive treatment, rising incidence of breast cancer, and improving healthcare infrastructure are driving the growth of breast cancer liquid biopsy market in this region.

Break of primary participants was as mentioned below:

- By Company Type - Tier 1- 15%, Tier 2- 45%, and Tier 3-40%
- By Designation - C-level- 27%, Director Level-33%, Others-40%
- By Region - North America-25%, Europe-45%, Asia-Pacific-15%, RoW-15%

Some of the major market players in the breast cancer liquid biopsy market are QIAGEN N.V. (Netherlands), Roche Diagnostics (US), Bio-Rad Laboratories (US), Myriad Genetics (US), Menarini Silicon Biosystems (Italy), Illumina (US), Cynvenio Biosystems, Inc. (US) Genomic Health, Inc. (US), Thermo Fisher Scientific Inc. (US), Fluxion Biosciences, Inc. (US), Biodesix, Inc. (US), Guardant Health, Inc. (US), and Isogen Life Science B.V. (Netherlands).

Research Coverage:

The report analyzes the breast cancer liquid biopsy market and aims at estimating market size and future growth potential of this market based on various segments such as by circulating biomarker, end user, and region. The report also includes competitive analysis of the key players in this market along with their company profiles, product offerings, recent developments, and key market strategies.

Reasons to Buy the Report

The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a greater share. Firms purchasing the report could use one or any combination of the below-mentioned five strategies.

This report provides insights on the following pointers:

- Market Penetration: Comprehensive information on product portfolios offered by the top players in the global liquid biopsy market. The report analyzes the global liquid biopsy market by product, medical specialty, application, end user, and region
- Innovation: Detailed insights on upcoming trends and product launches in the global breast cancer liquid biopsy market
- Market Development: Comprehensive information on the lucrative emerging markets by product, circulating biomarkers, end user, and region
- Market Diversification: Exhaustive information about growing geographies, recent developments, and investments in the global breast cancer liquid biopsy market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, products, and capabilities of liquid biopsy products of leading players in the global market



目次

1 LIQUID BIOPSY: MARKET AT A GLANCE
1.1  INTRODUCTION
1.2  ISSUES ADDRESSED BY LIQUID BIOPSY & BIOMARKERS DETECTED
1.3  MILESTONES IN LIQUID BIOPSY

2 LIQUID BIOPSY: CIRCULATING BIOMARKERS
2.1  LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR DNA (CTDNA)
2.2  CTDNA APPROACHES: APPLICATIONS AND LIMITATIONS
2.3  METHODS FOR CTC ISOLATION

3 LIQUID BIOPSY: MARKET OVERVIEW
3.1  INTRODUCTION
3.1.1 DRIVERS
3.1.2.1   HIGH BURDEN OF CANCER
3.1.2.2   INCREASING PREFERENCE FOR NONINVASIVE PROCEDURES
3.1.2.3   INITIATIVES UNDERTAKEN BY GOVERNMENTS
AND GLOBAL HEALTH ORGANIZATIONS                             
3.1.2.4  TECHNOLOGICAL ADVANCEMENTS
3.1.2.5  RISING EMPHASIS ON PERSONALIZED MEDICINE
3.1.2.6  AVAILABILITY OF FUNDING FOR LIQUID BIOPSY R&D
3.1.2     RESTRAINTS
3.1.2.1               LOW SENSITIVITY AND SPECIFICITY
3.1.3     OPPORTUNITIES
3.1.3.1               GROWING INTEREST IN LIQUID BIOPSY
3.1.4     CHALLENGES
3.1.4.1               UNCLEAR REGULATORY AND REIMBURSEMENT SCENARIO

4 MAJOR INVESTMENTS & INITIATIVES
4.1  GOVERNMENT FUNDING & INITIATIVES
4.2  INDUSTRY INVESTMENTS AND INITIATIVES

5 BREAST CANCER LIQUID BIOPSY MARKET
5.1 BREAST CANCER LIQUID BIOPSY MARKET: GLOBAL SCENARIO
5.2 POTENTIAL OF LIQUID BIOPSY AND CTC IN BREAST CANCER DIAGNOSIS
-
6 LIQUID BIOPSY MARKET: COMPETITIVE LANDSCAPE
6.1 INTRODUCTION
6.2  KEY STRATEGIES
6.2.1  ACQUISITIONS AND MERGERS 
6.2.2  PRODUCT LAUNCHES
6.2.3  AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS
6.3     LIQUID BIOPSY MARKET: COMPETITIVE TECHNOLOGY PORTFOLIO

7 APPENDIX
7.1 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
7.2 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
7.3 AVAILABLE CUSTOMIZATIONS
7.4               RELATED REPORTS
7.5 AUTHOR DETAILS
 

LIST OF TABLES

TABLE 1 CTDNA APPROACHES: APPLICATIONS AND LIMITATIONS
TABLE 2 METHODS FOR CTC ISOLATION-1
TABLE 3 METHODS FOR CTC ISOLATION -2
TABLE 4 CONFERENCES & AWARENESS PROGRAMS ON LIQUID BIOPSY
TABLE 5 UPCOMING CONFERENCES & AWARENESS PROGRAMS ON LIQUID BIOPSY
TABLE 6 GOVERNMENT FUNDING & INITIATIVES - NORTH AMERICA
TABLE 7 GOVERNMENT FUNDING & INITIATIVES - EUROPE
TABLE 8 GOVERNMENT FUNDING & INITIATIVES - ASIA PACIFIC
TABLE 9 GOVERNMENT FUNDING & INITIATIVES - REST OF THE WORLD
TABLE 10 MAJOR INVESTMENTS IN THE LIQUID BIOPSY MARKET (2010-2017) -1,2,3,4,5,6
TABLE 11 BREAST CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER,
2015-2022 (USD MILLION)
TABLE 12 BREAST CANCER LIQUID BIOPSY MARKET, BY REGION, 2015-2022 (USD MILLION)
TABLE 13 BREAST CANCER LIQUID BIOPSY MARKET, BY END USER,
2015-2022 (USD MILLION)
TABLE 14 BREAST CANCER CTDNA MARKET, BY REGION, 2015-2022 (USD MILLION)
TABLE 15 MAJOR PLAYERS AND COMPETITIVE TECHNOLOGY PORTFOLIO - 1,2,3,4,5,6,7
 

LIST OF FIGURES

FIGURE 1 ISSUES ADDRESSED BY LIQUID BIOPSY
FIGURE 2 LIQUID BIOPSY: DETECTION OF CANCER BIOMARKERS
FIGURE 3 MILESTONES IN LIQUID BIOPSY
FIGURE 4 LIQUID BIOPSY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 5 GLOBAL CANCER MORTALITY STATISTICS (2012)
FIGURE 6 BIOMARKERS USED IN CURRENT LIQUID BIOPSY TESTS
FIGURE 7 PUBMED PUBLICATIONS ON LIQUID BIOPSY
FIGURE 8 INVESTMENTS IN LIQUID BIOPSY: 2016 & 2017 (USED MILLION)
FIGURE 9 NGS FUND-RAISING IN 2017 (USD MILLION)
FIGURE 10 BREAST CANCER LIQUID BIOPSY: MARKET OVERVIEW
FIGURE 11 LIQUID BIOPSY MARKET BY CIRCULATING BIOMARKERS (CAGR 2017 - 2022)

 

ページTOPに戻る

プレスリリース

[プレスリリース原文]

Breast Cancer Liquid Biopsy Market worth $411.1 million by 2022


August 3, 2018

The report "Breast Cancer Liquid Biopsy Market by Circulating Biomarkers, Region, End User, Investments, Market Dynamics, Platform Comparison (NGS, PCR), Competitive Landscape (Acquisition, Mergers, Collaboration, Competitive technology) - Global Forecasts to 2022", The breast cancer liquid biopsy market is expected to reach USD 411.1 million by 2022 from USD 145.4 million in 2017, at a CAGR of 23.1%. The key factors driving the growth of this market include increasing prevalence of breast cancer, increasing preference for noninvasive procedures, initiatives undertaken by government and global health organizations, technological advancement to augment market revenues, rising emphasis on personalized medicine, and availability of funding for liquid biopsy R&D.

By circulating biomarkers, cell-free DNA (cfDNA) is expected to account for the largest market share in 2017

Based on circulating biomarkers, the market is categorized into circulating tumor cells (CTCs), cell-free DNA (cfDNA), extracellular vesicles (EVs), and other circulating biomarkers. In 2017, the cfDNA segment is expected to account for the largest share of the breast cancer liquid biopsy market. The ability of cfDNA for easy and early assessment of patient prognosis and occurrence in other body fluids along with blood is driving the growth of the cfDNA segment in the breast cancer liquid biopsy market.

By end user, the reference laboratories segment accounted for the largest market share in 2017

Based on end user, the breast cancer liquid biopsy market is segmented into reference laboratories, hospitals and physician laboratories, and other end users (research institutes, public health laboratories, pathology laboratories, and small molecular laboratories). Reference laboratories form the largest and fastest-growing end-user segment of the liquid biopsy market. The large share of this segment is attributed to the increasing volume of liquid biopsy test samples outsourced to reference laboratories owing to their well-equipped set up for genetic testing.

North America dominated the market in 2017

North America accounted for the largest share of the breast cancer liquid biopsy market in 2017, followed by Europe. A number of factors such as the easy accessibility and high adoption of advanced diagnostic technologies (such as PCR and NGS) among healthcare professionals, rising prevalence of breast cancer in the US and Canada, technological advancements in breast cancer liquid biopsy products, and growing public and private funding to support research activities in the field of liquid biopsy are aiding market growth in the region.

The key players in the global breast cancer liquid biopsy market are QIAGEN N.V. (Netherlands), Roche Diagnostics (US), Bio-Rad Laboratories Inc. (US), Myriad Genetics, Inc. (US), Menarini Silicon Biosystems (Italy), Genomic Health, Inc. (US), Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), Biocept, Inc. (US), Trovagene, Inc. (US), Guardant Health, Inc. (US), RainDance Technologies, Inc. (US), and MDx Health SA (US).

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る